Feb 17, 2021
SCYNEXIS and Hansoh Pharma announce licensing agreement and strategic partnership for Ibrexafungerp in Greater China
SCYNEXIS and Hansoh Pharma announce licensing agreement and strategic partnership for Ibrexafungerp in Greater China
Partnership aims to accelerate access to breakthrough therapies in order to combat difficult-to-treat and often drug-resistant fungal infections in Greater China SCYNEXIS will receive a $10 million upfront payment and will also be eligible to receive development and commercial milestones, plus low double-digit royalties on net product sales Ibrexafungerp is a first-in-class, broad-spectrum…
View On WordPress